LZI Carisoprodol Metabolite (Meprobamate) Enzyme Immunoassay

LZI Carisoprodol Metabolite (Meprobamate) Enzyme Immunoassay is an FDA 510(k)-cleared medical device (DEN170010) manufactured by Lin-Zhi International, Inc.. This device is classified under the Clinical Toxicology specialty. FDA Device Class II (Special Controls) — moderate risk, requires 510(k) clearance. FDA clearance granted on April 19, 2018. Regulation: 8.